Infants with colic cry less with BioGaia’s drops, study finds

Fourth positive study with Lactobacillus reuteri Protectis

A small North American study of 52 infants with colic has shown that babies given Lactobacillus reuteri Protectis, manufactured by Swedish healthcare BioGaia, cry and fuss less compared with babies given placebo. The newly published study is the fourth positive colic study with Lactobacillus reuteri Protectis and confirm the positive results of earlier studies.

'Infantile colic is one of the major concerns of many parents of babies, and for a long time, doctors and parents alike have struggled with a lack of treatment options to ease colic symptoms in early infancy,' said Gideon Koren, Professor at the University of Toronto and Senior Scientist at The Hospital for Sick Children, Toronto, Canada, where the study was carried out.

'It is critical to evaluate probiotics with the same scientific rigour used for medicinal drugs. Using these rigorous methods, we have shown that this probiotic can help infants.'

After seven days of treatment, crying and fussing was reduced by more than 40 minutes a day in infants given Lactobacillus reuteri Protectis, whereas there was practically no reduction in the placebo group. This behaviour continued to decrease significantly in the Lactobacillus reuteri Protectis group throughout the 21-day long study period. In the placebo group this decrease was significantly smaller.

The study was published in the Journal of Pediatrics.

'With this study – the fourth independent, positive study with Lactobacillus reuteri Protectis on colic – we further strengthen our position in the paediatric field. Furthermore, it is valuable that we now also have strong data in this field from a study conducted in North America”, said Peter Rothschild, President, BioGaia.

Companies